| TITRE |
Étude pilote de phase II sur l'effet du méthylphénidate sur la fonction cognitive des patientes en rémission d'un cancer du sein |
| PROTOCOLE ID |
CogMet |
| CLINICAL TRIAL.gov ID |
NCT02970500 |
| TYPE(S) DE CANCER |
Sein |
| PHASE |
Phase II |
| TYPE D'ÉTUDE |
Support |
| INSTITUTION |
CISSS DE CHAUDIERE-APPALACHES
253, ROUTE 108
(418) 774-3304
|
| VILLE |
Beauceville
|
| INVESTIGATEUR(RICE) PRINCIPAL(E) |
Anne Dagnault
|
| COORDONATEUR(RICE) |
Pierre Bédard
pierre_bedard@ssss.gouv.qc.ca
418-835-7121
|
| STATUT |
Fermé
|
| CRITÈRES D'ÉLIGIBILITÉ |
(EN)
- Breast cancer stade I, II or III
- had received chemotherapy and/or radiotherapy
- being in remission of her breast cancer
- complaining of cognitive impairment
|
| CRITÈRES D'EXCLUSION |
(EN)
- Current or recent use of psychostimulant drugs
-
Women receiving drugs like:
-
Anticoagulants
-
Antidepressants
-
Drugs (cocaine)
-
Erythropoietin
-
Drugs acting on the cerebral dopaminergic system, including drugs that inhibit monoamine oxidase
-
Currently taking John's wort, natural medicines for depression or supplements for fatigue.
- Conditions that may increase the risk of cognitive impairment or toxicity of methylphenidate such as :
- Pregnancy and breastfeeding
- Migraine, headache
- Bipolar status
- Cerebral tumor or any brain injury
- Metastatic cancer
- Alcohol addiction
- Drug
- Active Major depression
- Parkinson disease
- Dementia
- Epilepsia,
- Glaucoma
- Cardiovascular diseases
- Auto-immunes and chronic inflammatory disease
- Narcolepsia
- Pheochromocytome
- Thyrotoxicosis
- Motor tic, Gilles de la Tourette syndrome
- Anxiety
|
